Effects of menatetrenone on the bone and calcium metabolism in osteoporosis: A double-blind placebo-controlled study View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1998-06

AUTHORS

Hajime Orimo, Masataka Shiraki, Akio Tomita, Hirotoshi Morii, Takuo Fujita, Masahiro Ohata

ABSTRACT

: Menatetrenone (2-methyl 1,3-tetraprenyl-1,4-naphtoquinone; vitamin K2) is a vitamin K homolog. To evaluate its efficacy on cortical bone mineral density and its safety, a 24-week double-blind placebo-controlled study was conducted by enrolling 80 osteoporotic patients. Patients were given either 90 mg/day of vitamin K2 (n = 39) or a placebo (n = 41). Bone density was assessed on the X-ray film of the right second metacarpal bone using the microdensitometric method. In the vitamin K2 group, bone density increased by 2.20% ± 2.48% from the baseline; in the placebo group, it decreased by −7.31% ± 3.65% (P = .037, K2vs placebo). Urinary excretion of γ-carboxyglutamic acid (Gla) significantly increased from 72.61 ± 4.08 nmole/mg creatinine before treatment to 88.36 ± 5.35 in the 24th week after completion of the vitamin K2 treatment (P = .008). In the placebo group, there were no significant changes in urinary Gla excretion. In the 24th week of the treatment, the urinary calcium/creatinine ratio in the vitamin K2 group decreased from 0.137 ± 0.018 to 0.118 ± 0.016; in the placebo group, it increased from 0.153 ± 0.018 to 0.189 ± 0.029. As a result, the 24-week levels in the vitamin K2 and placebo groups became significantly different (P = .028). There were a few adverse effects attributable to vitamin K2. Our findings suggest that vitamin K2 at a dosage of 90 mg/day is effective in maintaining peripheral cortical bone density and is safe in treatment for osteoporosis. More... »

PAGES

106-112

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s007740050034

DOI

http://dx.doi.org/10.1007/s007740050034

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1012224208


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Tokyo Metropolitan Geriatric Hospital, 2-35 Sakae-cho, Itabashi, Tokyo 173-0015, Japan, JP", 
          "id": "http://www.grid.ac/institutes/grid.417092.9", 
          "name": [
            "Tokyo Metropolitan Geriatric Hospital, 2-35 Sakae-cho, Itabashi, Tokyo 173-0015, Japan, JP"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Orimo", 
        "givenName": "Hajime", 
        "id": "sg:person.0765441146.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0765441146.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Institute and Practice for Involutional Diseases, 1609 Meisei, Misatomura, Minamiazumigum, Nagano 399-8101, Japan, JP", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Research Institute and Practice for Involutional Diseases, 1609 Meisei, Misatomura, Minamiazumigum, Nagano 399-8101, Japan, JP"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shiraki", 
        "givenName": "Masataka", 
        "id": "sg:person.01030622354.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030622354.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Aichi Medical University, 2-12-1 Higashisakura, Higashi-ku, Nagoya, Aichi 461-0005, Japan, JP", 
          "id": "http://www.grid.ac/institutes/grid.411234.1", 
          "name": [
            "Aichi Medical University, 2-12-1 Higashisakura, Higashi-ku, Nagoya, Aichi 461-0005, Japan, JP"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tomita", 
        "givenName": "Akio", 
        "id": "sg:person.0635407407.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635407407.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Second Department of Internal Medicine, Osaka City University, Medical School, 1-5-7 Asahimachi, Abeno-ku, Osaka 545-0051, Japan, JP", 
          "id": "http://www.grid.ac/institutes/grid.261445.0", 
          "name": [
            "Second Department of Internal Medicine, Osaka City University, Medical School, 1-5-7 Asahimachi, Abeno-ku, Osaka 545-0051, Japan, JP"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morii", 
        "givenName": "Hirotoshi", 
        "id": "sg:person.01340465204.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340465204.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Calcium Research Institute, 250 Makamicho, Kishiwada, Osaka 596-0842, Japan, JP", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Calcium Research Institute, 250 Makamicho, Kishiwada, Osaka 596-0842, Japan, JP"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fujita", 
        "givenName": "Takuo", 
        "id": "sg:person.07434721012.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07434721012.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Wakayama Medical College, Kihoku Branch Hospital, 219 Myoji, Katsuragi-cho, Itogun, Wakayama 649-7113, Japan, JP", 
          "id": "http://www.grid.ac/institutes/grid.412857.d", 
          "name": [
            "Department of Internal Medicine, Wakayama Medical College, Kihoku Branch Hospital, 219 Myoji, Katsuragi-cho, Itogun, Wakayama 649-7113, Japan, JP"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ohata", 
        "givenName": "Masahiro", 
        "id": "sg:person.0636424326.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636424326.31"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf02554833", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052584427", 
          "https://doi.org/10.1007/bf02554833"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00299308", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009328233", 
          "https://doi.org/10.1007/bf00299308"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1998-06", 
    "datePublishedReg": "1998-06-01", 
    "description": "Abstract: Menatetrenone (2-methyl 1,3-tetraprenyl-1,4-naphtoquinone; vitamin K2) is a vitamin K homolog. To evaluate its efficacy on cortical bone mineral density and its safety, a 24-week double-blind placebo-controlled study was conducted by enrolling 80 osteoporotic patients. Patients were given either 90 mg/day of vitamin K2 (n = 39) or a placebo (n = 41). Bone density was assessed on the X-ray film of the right second metacarpal bone using the microdensitometric method. In the vitamin K2 group, bone density increased by 2.20% \u00b1 2.48% from the baseline; in the placebo group, it decreased by \u22127.31% \u00b1 3.65% (P = .037, K2vs placebo). Urinary excretion of \u03b3-carboxyglutamic acid (Gla) significantly increased from 72.61 \u00b1 4.08 nmole/mg creatinine before treatment to 88.36 \u00b1 5.35 in the 24th week after completion of the vitamin K2 treatment (P = .008). In the placebo group, there were no significant changes in urinary Gla excretion. In the 24th week of the treatment, the urinary calcium/creatinine ratio in the vitamin K2 group decreased from 0.137 \u00b1 0.018 to 0.118 \u00b1 0.016; in the placebo group, it increased from 0.153 \u00b1 0.018 to 0.189 \u00b1 0.029. As a result, the 24-week levels in the vitamin K2 and placebo groups became significantly different (P = .028). There were a few adverse effects attributable to vitamin K2. Our findings suggest that vitamin K2 at a dosage of 90 mg/day is effective in maintaining peripheral cortical bone density and is safe in treatment for osteoporosis.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s007740050034", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1312216", 
        "issn": [
          "0914-8779", 
          "1435-5604"
        ], 
        "name": "Journal of Bone and Mineral Metabolism", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "16"
      }
    ], 
    "keywords": [
      "double-blind placebo-controlled study", 
      "placebo-controlled study", 
      "placebo group", 
      "vitamin K2 group", 
      "bone density", 
      "vitamin K2", 
      "K2 group", 
      "urinary calcium/creatinine ratio", 
      "calcium/creatinine ratio", 
      "cortical bone mineral density", 
      "urinary Gla excretion", 
      "effects of menatetrenone", 
      "vitamin K2 treatment", 
      "cortical bone density", 
      "bone mineral density", 
      "second metacarpal bone", 
      "vitamin K homologs", 
      "creatinine ratio", 
      "osteoporotic patients", 
      "urinary excretion", 
      "calcium metabolism", 
      "mineral density", 
      "Gla excretion", 
      "K2 treatment", 
      "metacarpal bone", 
      "adverse effects", 
      "ray films", 
      "microdensitometric method", 
      "patients", 
      "osteoporosis", 
      "treatment", 
      "menatetrenone", 
      "excretion", 
      "weeks", 
      "significant changes", 
      "bone", 
      "group", 
      "days", 
      "placebo", 
      "carboxyglutamic acid", 
      "creatinine", 
      "baseline", 
      "efficacy", 
      "study", 
      "dosage", 
      "metabolism", 
      "safety", 
      "effect", 
      "findings", 
      "completion", 
      "levels", 
      "changes", 
      "acid", 
      "ratio", 
      "results", 
      "K2", 
      "density", 
      "homolog", 
      "method", 
      "films", 
      "K homolog", 
      "right second metacarpal bone", 
      "peripheral cortical bone density"
    ], 
    "name": "Effects of menatetrenone on the bone and calcium metabolism in osteoporosis: A double-blind placebo-controlled study", 
    "pagination": "106-112", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1012224208"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s007740050034"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s007740050034", 
      "https://app.dimensions.ai/details/publication/pub.1012224208"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:11", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_306.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s007740050034"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s007740050034'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s007740050034'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s007740050034'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s007740050034'


 

This table displays all metadata directly associated to this object as RDF triples.

178 TRIPLES      22 PREDICATES      91 URIs      81 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s007740050034 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Nb827a8e04819433380196621efed9db2
4 schema:citation sg:pub.10.1007/bf00299308
5 sg:pub.10.1007/bf02554833
6 schema:datePublished 1998-06
7 schema:datePublishedReg 1998-06-01
8 schema:description Abstract: Menatetrenone (2-methyl 1,3-tetraprenyl-1,4-naphtoquinone; vitamin K2) is a vitamin K homolog. To evaluate its efficacy on cortical bone mineral density and its safety, a 24-week double-blind placebo-controlled study was conducted by enrolling 80 osteoporotic patients. Patients were given either 90 mg/day of vitamin K2 (n = 39) or a placebo (n = 41). Bone density was assessed on the X-ray film of the right second metacarpal bone using the microdensitometric method. In the vitamin K2 group, bone density increased by 2.20% ± 2.48% from the baseline; in the placebo group, it decreased by −7.31% ± 3.65% (P = .037, K2vs placebo). Urinary excretion of γ-carboxyglutamic acid (Gla) significantly increased from 72.61 ± 4.08 nmole/mg creatinine before treatment to 88.36 ± 5.35 in the 24th week after completion of the vitamin K2 treatment (P = .008). In the placebo group, there were no significant changes in urinary Gla excretion. In the 24th week of the treatment, the urinary calcium/creatinine ratio in the vitamin K2 group decreased from 0.137 ± 0.018 to 0.118 ± 0.016; in the placebo group, it increased from 0.153 ± 0.018 to 0.189 ± 0.029. As a result, the 24-week levels in the vitamin K2 and placebo groups became significantly different (P = .028). There were a few adverse effects attributable to vitamin K2. Our findings suggest that vitamin K2 at a dosage of 90 mg/day is effective in maintaining peripheral cortical bone density and is safe in treatment for osteoporosis.
9 schema:genre article
10 schema:inLanguage en
11 schema:isAccessibleForFree false
12 schema:isPartOf N561520ba62c5475d9acaaf11f6d57b5f
13 Nb948408bd6cf4262b070ee21ca736896
14 sg:journal.1312216
15 schema:keywords Gla excretion
16 K homolog
17 K2
18 K2 group
19 K2 treatment
20 acid
21 adverse effects
22 baseline
23 bone
24 bone density
25 bone mineral density
26 calcium metabolism
27 calcium/creatinine ratio
28 carboxyglutamic acid
29 changes
30 completion
31 cortical bone density
32 cortical bone mineral density
33 creatinine
34 creatinine ratio
35 days
36 density
37 dosage
38 double-blind placebo-controlled study
39 effect
40 effects of menatetrenone
41 efficacy
42 excretion
43 films
44 findings
45 group
46 homolog
47 levels
48 menatetrenone
49 metabolism
50 metacarpal bone
51 method
52 microdensitometric method
53 mineral density
54 osteoporosis
55 osteoporotic patients
56 patients
57 peripheral cortical bone density
58 placebo
59 placebo group
60 placebo-controlled study
61 ratio
62 ray films
63 results
64 right second metacarpal bone
65 safety
66 second metacarpal bone
67 significant changes
68 study
69 treatment
70 urinary Gla excretion
71 urinary calcium/creatinine ratio
72 urinary excretion
73 vitamin K homologs
74 vitamin K2
75 vitamin K2 group
76 vitamin K2 treatment
77 weeks
78 schema:name Effects of menatetrenone on the bone and calcium metabolism in osteoporosis: A double-blind placebo-controlled study
79 schema:pagination 106-112
80 schema:productId N88976acb5ed44e8cb7d61404a929ebf9
81 Nba1c674ef7fd4e57a1c68db6e94aee99
82 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012224208
83 https://doi.org/10.1007/s007740050034
84 schema:sdDatePublished 2021-12-01T19:11
85 schema:sdLicense https://scigraph.springernature.com/explorer/license/
86 schema:sdPublisher Nc67aa1c6606f4274815f64029db0c84b
87 schema:url https://doi.org/10.1007/s007740050034
88 sgo:license sg:explorer/license/
89 sgo:sdDataset articles
90 rdf:type schema:ScholarlyArticle
91 N561520ba62c5475d9acaaf11f6d57b5f schema:volumeNumber 16
92 rdf:type schema:PublicationVolume
93 N6262843dfd9f4e3a8bfe1242fb6cb8f9 rdf:first sg:person.01030622354.12
94 rdf:rest Nc5343ec62dd04ec7876727357df71802
95 N88976acb5ed44e8cb7d61404a929ebf9 schema:name doi
96 schema:value 10.1007/s007740050034
97 rdf:type schema:PropertyValue
98 N9e98863961e345948e6d4da43f46545f rdf:first sg:person.07434721012.68
99 rdf:rest Nfa79daddbdd0453d82b8673dc3dde2bd
100 Nb827a8e04819433380196621efed9db2 rdf:first sg:person.0765441146.28
101 rdf:rest N6262843dfd9f4e3a8bfe1242fb6cb8f9
102 Nb948408bd6cf4262b070ee21ca736896 schema:issueNumber 2
103 rdf:type schema:PublicationIssue
104 Nba1c674ef7fd4e57a1c68db6e94aee99 schema:name dimensions_id
105 schema:value pub.1012224208
106 rdf:type schema:PropertyValue
107 Nc5343ec62dd04ec7876727357df71802 rdf:first sg:person.0635407407.86
108 rdf:rest Ne120c809cd40451da5cb8077b8ba2f13
109 Nc67aa1c6606f4274815f64029db0c84b schema:name Springer Nature - SN SciGraph project
110 rdf:type schema:Organization
111 Ne120c809cd40451da5cb8077b8ba2f13 rdf:first sg:person.01340465204.76
112 rdf:rest N9e98863961e345948e6d4da43f46545f
113 Nfa79daddbdd0453d82b8673dc3dde2bd rdf:first sg:person.0636424326.31
114 rdf:rest rdf:nil
115 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
116 schema:name Medical and Health Sciences
117 rdf:type schema:DefinedTerm
118 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
119 schema:name Clinical Sciences
120 rdf:type schema:DefinedTerm
121 sg:journal.1312216 schema:issn 0914-8779
122 1435-5604
123 schema:name Journal of Bone and Mineral Metabolism
124 schema:publisher Springer Nature
125 rdf:type schema:Periodical
126 sg:person.01030622354.12 schema:affiliation grid-institutes:None
127 schema:familyName Shiraki
128 schema:givenName Masataka
129 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030622354.12
130 rdf:type schema:Person
131 sg:person.01340465204.76 schema:affiliation grid-institutes:grid.261445.0
132 schema:familyName Morii
133 schema:givenName Hirotoshi
134 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340465204.76
135 rdf:type schema:Person
136 sg:person.0635407407.86 schema:affiliation grid-institutes:grid.411234.1
137 schema:familyName Tomita
138 schema:givenName Akio
139 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635407407.86
140 rdf:type schema:Person
141 sg:person.0636424326.31 schema:affiliation grid-institutes:grid.412857.d
142 schema:familyName Ohata
143 schema:givenName Masahiro
144 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636424326.31
145 rdf:type schema:Person
146 sg:person.07434721012.68 schema:affiliation grid-institutes:None
147 schema:familyName Fujita
148 schema:givenName Takuo
149 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07434721012.68
150 rdf:type schema:Person
151 sg:person.0765441146.28 schema:affiliation grid-institutes:grid.417092.9
152 schema:familyName Orimo
153 schema:givenName Hajime
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0765441146.28
155 rdf:type schema:Person
156 sg:pub.10.1007/bf00299308 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009328233
157 https://doi.org/10.1007/bf00299308
158 rdf:type schema:CreativeWork
159 sg:pub.10.1007/bf02554833 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052584427
160 https://doi.org/10.1007/bf02554833
161 rdf:type schema:CreativeWork
162 grid-institutes:None schema:alternateName Calcium Research Institute, 250 Makamicho, Kishiwada, Osaka 596-0842, Japan, JP
163 Research Institute and Practice for Involutional Diseases, 1609 Meisei, Misatomura, Minamiazumigum, Nagano 399-8101, Japan, JP
164 schema:name Calcium Research Institute, 250 Makamicho, Kishiwada, Osaka 596-0842, Japan, JP
165 Research Institute and Practice for Involutional Diseases, 1609 Meisei, Misatomura, Minamiazumigum, Nagano 399-8101, Japan, JP
166 rdf:type schema:Organization
167 grid-institutes:grid.261445.0 schema:alternateName Second Department of Internal Medicine, Osaka City University, Medical School, 1-5-7 Asahimachi, Abeno-ku, Osaka 545-0051, Japan, JP
168 schema:name Second Department of Internal Medicine, Osaka City University, Medical School, 1-5-7 Asahimachi, Abeno-ku, Osaka 545-0051, Japan, JP
169 rdf:type schema:Organization
170 grid-institutes:grid.411234.1 schema:alternateName Aichi Medical University, 2-12-1 Higashisakura, Higashi-ku, Nagoya, Aichi 461-0005, Japan, JP
171 schema:name Aichi Medical University, 2-12-1 Higashisakura, Higashi-ku, Nagoya, Aichi 461-0005, Japan, JP
172 rdf:type schema:Organization
173 grid-institutes:grid.412857.d schema:alternateName Department of Internal Medicine, Wakayama Medical College, Kihoku Branch Hospital, 219 Myoji, Katsuragi-cho, Itogun, Wakayama 649-7113, Japan, JP
174 schema:name Department of Internal Medicine, Wakayama Medical College, Kihoku Branch Hospital, 219 Myoji, Katsuragi-cho, Itogun, Wakayama 649-7113, Japan, JP
175 rdf:type schema:Organization
176 grid-institutes:grid.417092.9 schema:alternateName Tokyo Metropolitan Geriatric Hospital, 2-35 Sakae-cho, Itabashi, Tokyo 173-0015, Japan, JP
177 schema:name Tokyo Metropolitan Geriatric Hospital, 2-35 Sakae-cho, Itabashi, Tokyo 173-0015, Japan, JP
178 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...